Panthera is on track to have a network of sites open across the UK by the end of the year.
“We are adapting our plans to support the efforts of those tackling the COVID-19 pandemic while also pursuing the long-term goal to provide exemplar, independently run clinical trial sites across the UK and beyond. We are already able to provide top class clinical facilities in Preston and Manchester and are looking to build that network much further putting the patient at the heart of what we do,” CEO Stuart Young said. “This pandemic has highlighted the need for more clinical research across the globe. We are keen to play our part to help in the short term in any way we can. However, in the longer term, we are focussed on providing our customers in pharma and CROs with a better solution.”
Panthera, as an independent SMO, has attracted the attention of CROs and pharma companies, and is offering sites for their traditional specialities in vaccines, general medicine and primary care conditions.
Panthera is also in advanced discussions in providing specialist secondary care sites for trials in neurology and oncology.
Founded by Dr Ian Smith, founder of Synexus, and Prof. John Lyon previously a senior global executive in Covance, the team also includes CCO Jane Restorick who was previously the global COO at Synexus and CEO Stuart Young, former MD Synexus UK.
The site facilities will include seven consulting rooms, a fully equipped laboratory, with state of the art research facilities and ample parking for patients.